Lantheus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Lantheus and other ETFs, options, and stocks.

About LNTH

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. 

CEO
Mary Anne Heino
CEOMary Anne Heino
Employees
1,193
Employees1,193
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
1956
Founded1956
Employees
1,193
Employees1,193

LNTH Key Statistics

Market cap
6.47B
Market cap6.47B
Price-Earnings ratio
23.95
Price-Earnings ratio23.95
Dividend yield
Dividend yield
Average volume
1.24M
Average volume1.24M
High today
$100.64
High today$100.64
Low today
$97.86
Low today$97.86
Open price
$99.13
Open price$99.13
Volume
1.38M
Volume1.38M
52 Week high
$103.89
52 Week high$103.89
52 Week low
$47.25
52 Week low$47.25

Stock Snapshot

Lantheus(LNTH) stock is priced at $99.00, giving the company a market capitalization of 6.47B. It carries a P/E multiple of 23.95.

During the trading session on 2026-05-31, Lantheus(LNTH) shares reached a daily high of $100.64 and a low of $97.86. At a current price of $99.00, the stock is +1.2% higher than the low and still -1.6% under the high.

Trading volume for Lantheus(LNTH) stock has reached 1.38M, versus its average volume of 1.24M.

The stock's 52-week range extends from a low of $47.25 to a high of $103.89.

The stock's 52-week range extends from a low of $47.25 to a high of $103.89.

LNTH News

Simply Wall St 1d
Assessing Lantheus Holdings Valuation As New ASCO 2026 Oncology Data Nears Publication

Lantheus Holdings (LNTH) is drawing fresh attention after announcing that new clinical and real world oncology data will be featured at the 2026 American Societ...

Assessing Lantheus Holdings Valuation As New ASCO 2026 Oncology Data Nears Publication
Simply Wall St 2d
Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative

Lantheus Holdings (NasdaqGM:LNTH) plans to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical, at the 2026 ASCO Annual Meeting. Th...

Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative

Analyst ratings

79%

of 14 ratings
Buy
78.6%
Hold
21.4%
Sell
0%

People also own

Based on the portfolios of people who own LNTH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.